Loading...
XKRX
092040
Market cap54mUSD
Jun 05, Last price  
3,800.00KRW
1D
-17.30%
1Q
2.84%
Jan 2017
-82.68%
IPO
-90.13%
Name

Amicogen Inc

Chart & Performance

D1W1MN
P/E
—
P/S
0.43
EPS
—
Div Yield, %
—
Shrs. gr., 5y
5.65%
Rev. gr., 5y
8.55%
Revenues
173.60b
+8.57%
23,180,942,20027,331,643,81032,457,291,97268,968,044,74473,665,135,17494,521,965,173115,180,889,376115,856,068,707124,880,967,146144,295,727,345159,904,289,100173,604,673,960
Net income
-52.79b
L+126.68%
7,574,696,3207,563,006,7302,065,660,8631,588,678,628-4,605,846,38240,168,083,20686,718,41331,604,368,9803,732,651,380-47,219,840,701-23,288,915,560-52,791,134,750
CFO
-13.34b
L
6,623,420,9804,425,691,46012,342,714,19411,276,966,40811,882,053,2712,840,022,7428,760,340,9278,865,817,7798,073,460,493-22,413,068,1208,642,674,520-13,335,192,710
Dividend
Dec 29, 2015200 KRW/sh
Earnings
Aug 12, 2025

Profile

Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company offers specialty enzymes, including CX, SP, etc. for pharmaceutical, food, chemical, and energy industries. It also provides new bio-ingredients, such as N-acetylglucosamine for skin moisturizing and joint health; pinitol/D-chiro-inositol; collagen peptide and collagen tripeptide for skin and health; chitoslim and chitosan oligosaccharides; and lactic acid bacteria, as well as fucoxanthin, curezyme, food enzyme, and bamboo salt. In addition, the company offers K-nutra, a healthcare brand; and KeyClean, a disinfectant brand. Further, it provides protein purification resins. The company was founded in 2000 and is headquartered in Jinju-si, South Korea.
URL
http://www.amicogen.com/
IPO date
Sep 12, 2013
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
173,604,674
8.57%
159,904,289
10.82%
144,295,727
15.55%
Cost of revenue
153,225,857
134,011,241
130,807,558
Unusual Expense (Income)
NOPBT
20,378,817
25,893,048
13,488,169
NOPBT Margin
11.74%
16.19%
9.35%
Operating Taxes
343,340
(2,540,477)
(4,780,365)
Tax Rate
1.68%
NOPAT
20,035,477
28,433,525
18,268,534
Net income
(52,791,135)
126.68%
(23,288,916)
-50.68%
(47,219,841)
-1,365.05%
Dividends
Dividend yield
Proceeds from repurchase of equity
70,301,000
(34,215)
BB yield
-23.30%
0.01%
Debt
Debt current
50,462,624
78,425,248
94,169,622
Long-term debt
70,862,320
72,329,723
50,308,424
Deferred revenue
577,363
Other long-term liabilities
2,143,967
2,071,214
1,361,673
Net debt
86,798,865
45,165,200
15,747,510
Cash flow
Cash from operating activities
(13,335,193)
8,642,675
(22,413,068)
CAPEX
(47,681,763)
(62,515,821)
(47,320,437)
Cash from investing activities
(23,682,017)
(58,260,217)
(70,435,388)
Cash from financing activities
16,578,569
54,181,074
87,629,432
FCF
71,784,376
(46,697,188)
(15,557,942)
Balance
Cash
8,454,982
38,554,888
34,686,354
Long term investments
26,071,097
67,034,882
94,044,183
Excess cash
25,845,845
97,594,556
121,515,750
Stockholders' equity
(10,526,843)
86,624,258
89,073,428
Invested Capital
255,137,381
284,015,865
226,044,230
ROIC
7.43%
11.15%
9.49%
ROCE
8.30%
6.99%
4.24%
EV
Common stock shares outstanding
54,790
39,907
42,827
Price
3,860.00
-48.94%
7,560.00
-15.52%
8,948.39
-38.90%
Market cap
211,487,605
-29.90%
301,695,423
-21.28%
383,231,177
-37.83%
EV
298,888,334
389,992,013
436,959,774
EBITDA
34,332,705
39,156,723
26,153,294
EV/EBITDA
8.71
9.96
16.71
Interest
10,241,076
11,335,411
7,459,638
Interest/NOPBT
50.25%
43.78%
55.31%